Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The present invention further relates to a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies related thereto.

Abstract: The present invention relates to a dry pharmaceutical composition for inhalation comprising an antigen and an amphiphilic immune stimulant, wherein said pharmaceutical composition was produced by spray-drying; and to a dry pharmaceutical composition obtained or obtainable by spray-drying a solution comprising an antigen, an amphiphilic immune stimulant, and, optionally, a bulking agent. The present invention also relates to said dry pharmaceutical composition for use in medicine, in particular for use in vaccination of a subject; and to methods and kits related thereto.

Abstract: The present invention relates to an immunogenic polypeptide comprising (i) a B-cell epitope, (ii) a T-cell epitope, and (iii) a scaffold polypeptide, wherein said scaffold polypeptide is a thioredoxin polypeptide. The present invention further relates to said immunogenic polypeptide for use in medicine and for use in treating and/or preventing inappropriate proliferation of cells and/or infection with an infectious agent, preferably HPV infection, as well as to polypeptides and vectors encoding said immunogenic polypeptide.

Abstract: The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.

Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The present invention further relates to a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies related thereto.

Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of human papillomavirus (HPV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least two different HPV genotypes. The present invention also relates to said immunogenic polypeptide for use in medicine and for use in vaccination against HPV infection. Moreover, the present invention relates to a polynucleotide encoding the immunogenic polypeptide and to a host cell comprising the same. Moreover, the present invention relates to kits, methods, and uses related to the immunogenic polypeptide of the invention.

Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of human papillomavirus (HPV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least two different HPV genotypes. The present invention also relates to said immunogenic polypeptide for use in medicine and for use in vaccination against HPV infection. Moreover, the present invention relates to a polynucleotide encoding the immunogenic polypeptide and to a host cell comprising the same. Moreover, the present invention relates to kits, methods, and uses related to the immunogenic polypeptide of the invention.

Abstract: The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.

Abstract: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.

Abstract: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.

Abstract: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.

Abstract: Polypeptide based on a tandem array of repeats of the N-terminal 7 amino acids of A?42, preferably positioned within the active loop site of a carrier such as bacterial thioredoxin (Trx) are useful for treating and/or preventing Alzheimer's disease. Antibodies raised against these recombinant constructs were found to have a very strong affinity for A?42.

Abstract: The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of A?42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Trx). Polypeptides bearing multiple copies of A?42 fragments, preferably with an interposed amino acid linker, were constructed and injected into mice in combination with an adjuvant. Monoclonal antibodies were made which recognize the immunogenic construct comprising a carrier bearing at least one fragment of A?42 within an active loop site of the carrier. The elicited antibodies were found to selectively bind to fibrillar and/or oligomers A? within neuritic AD plaques.

Abstract: The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of A?42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Yrx). Polypeptides bearing multiple copies of A?42 fragments, preferably with an interposed amino acid linker, were constructed and injected into mice in combination with an adjuvant. Elicited antibodies were found to selectively bind to fibrillar and/or oligomers A? within neuritic AD plaques.

Abstract: The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of A?42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Trx). Polypeptides bearing multiple copies of A?42 fragments, preferably with an interposed amino acid linker, were constructed and injected into mice in combination with an adjuvant. Elicited antibodies were found to selectively bind to fibrillar and/or oligomers A? within neuritic AD plaques.